Search
The Artificial Intelligence team at the Wal-yan Respiratory Research Centre is dedicated to delivering AI solutions for major challenges in respiratory healthcare and research.
Respiratory disease is a global issue and international networks are critical to informing best-practice approaches to the clinical care and management of childhood respiratory health.
Respiratory illness accounts for 12% of the age-standardised gap in mortality between Indigenous and non-Indigenous Australians.
Phage WA have a number of projects underway and these cover a broad range of phage research areas.
START Phage WA was formed to pave the way towards treating AMR infections with phage therapy in Western Australia.
"Compassionate Use" treatments are novel treatments not widely available to everyone, but ones that holds great promise for potentially becoming a widely used treatment in the future.
We've compiled a number of helpful links to phage resources in Australia and beyond.
Community involvement plays an integral role in guiding our research - find out how.
Infants with cystic fibrosis (CF) develop structural lung disease early in life, and viral infections are associated with progressive lung disease. We hypothesized that the presence of respiratory viruses would be associated with structural lung disease on computed tomography (CT) of the chest in infants with CF.
We tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.